Guinea-Bissau suspends controversial US-backed hepatitis vaccine trial

The West African nation of Guinea-Bissau has suspended a contentious clinical trial examining a hepatitis vaccine regimen in infants, following concerns from the medical community about ethical implications and potential harm to vulnerable populations.

The trial, funded by the United States, was designed to evaluate alternative vaccination schedules for hepatitis B protection. However, critics contended that the experimental design would deny standard immunization protocols to a control group of thousands of infants during the study period, raising serious questions about informed consent and medical ethics in resource-limited settings.

Health experts emphasized that hepatitis B vaccination is a critical public health intervention, particularly in countries where the disease burden remains significant. Withholding proven preventive measures from study participants, even temporarily, conflicts with established principles governing clinical research in vulnerable populations.

The suspension reflects growing international scrutiny of clinical trials conducted in developing nations, where questions persist regarding whether research protocols adequately protect participants' rights and welfare. The decision underscores the importance of ensuring that foreign-funded medical research meets stringent ethical standards and prioritizes the health interests of host communities.